Developing peptide vaccines for breast cancer

Theaker, Sarah M. 2018. Developing peptide vaccines for breast cancer. PhD Thesis, Cardiff University. Item availability restricted.

	PDF (PhD Thesis) - Accepted Post-Print Version Download (14MB)
	Microsoft Word (DOCX) (Thesis Publication Form) - Supplemental Material Restricted to Repository staff only Download (59kB)

Abstract

The complex and heterogeneous nature of breast cancer presents significant challenges for many conventional cancer therapies. Immunotherapy has the potential to provide a more potent, less invasive and less toxic approach to breast cancer treatment, with several successes already evident in the treatment of metastatic melanoma. Three recently described tumour-associated antigens (TAAs); (1) NY-BR-1, (2) cadherin-3/P-cadherin (CDH3), and (3) bone marrow stromal cell antigen-2 (BST-2), have been implicated as candidates for breast cancer vaccination strategies. However, peptide vaccines that are designed using wild-type (WT) sequences of these proteins are likely to elicit suboptimal T-cell responses in patients. This is generally attributable to the low affinity of thymically-selected Tcell receptors (TCRs) for “self” TAAs. Here I describe a method for enhancing the immunogenicity of these three HLA-A*0201 (HLA-A2)-restricted breast cancer epitopes. Firstly, αβ CD8+ T-cell clones were generated against each of the epitopes using three different approaches; (i) T-cell lines and (ii) T-cell libraries (Chapter 3),and (iii) tumour-infiltrating lymphocytes (TILs) (Chapter 4), and the breast cancer reactivity of these clones confirmed in vitro. Then, using a positional scanning synthetic combinatorial library (PS-SCL), altered peptide ligands (APLs) were designed for each of the clones (Chapter 5). These APLs were shown to be up to 100,000-fold more potent than the respective WT epitopes. Preliminary “proof-ofconcept” CD8+ T-cell priming experiments on healthy HLA-A2+ donors were then used to establish whether a chosen BST-2 APL was capable of activating superior breast cancer specific T-cell populations in vitro (Chapter 6). From these preliminary investigations, it was found that the BST-2 APL was capable of generating a T-cell response of greater magnitude, and that was also better able to kill breast cancer cells when compared to the corresponding BST-2 WT peptide. Together, these experiments illustrate the potential use of APLs for the development of a highly effective prophylactic or therapeutic peptide vaccine for breast cancer.

Item Type:	Thesis (PhD)
Date Type:	Completion
Status:	Unpublished
Schools:	Medicine
Funders:	Breast Cancer Now
Date of First Compliant Deposit:	1 August 2018
Last Modified:	19 Apr 2023 08:27
URI:	https://orca.cardiff.ac.uk/id/eprint/113785

Actions (repository staff only)

Edit Item